Drug Profile
Research programme: encapsulated cell therapies - Eli Lilly and Company/Sigilon Therapeutics
Latest Information Update: 18 Aug 2023
Price :
$50
*
At a glance
- Originator Sigilon Therapeutics
- Developer Eli Lilly and Company; Sigilon Therapeutics
- Class Antihyperglycaemics; Cell therapies; Gene therapies
- Mechanism of Action Pancreatic beta cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Type 1 diabetes mellitus
Most Recent Events
- 14 Aug 2023 Sigilon Therapeutics has been acquired by Eli Lilly and Company
- 28 May 2022 No recent reports of development identified for research development in Type-1 diabetes mellitus in United Kingdom
- 11 Jun 2019 Sigilon Therapeutics has patent protection for encapsulation techniques involved in Shielded Living Therapeutics™ in USA